CURX

Curanex Pharmaceuticals Inc

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.97
52-Week Range: $3.58 – $16.94
Market Cap: $7.40M
P/E (TTM): —
EPS (TTM): -7.80
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.40
PEG Ratio: —
Return on Equity: -411.08%
Return on Assets: -225.06%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 45.95
Debt/Equity: 0.06
Total Debt: $276.36K
Free Cash Flow: $-7.71M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.74M

CURX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$26.00K	$0.00	$0.00	$0.00
Cost of Revenue	$21.57K	$0.00	—	—
Gross Profit	$4.43K	$0.00	—	—
Research & Development	—	—	$0.00	$2.99M
Selling, General & Admin	$24.66K	$19.30K	$290.39K	$1.25M
Operating Expenses	$24.66K	$19.30K	$290.39K	$4.24M
Operating Income	-$20.23K	-$19.30K	-$290.39K	-$4.24M
EBITDA	$925.00	-$17.48K	-$361.51K	-$4.14M
Pretax Income	-$20.23K	-$19.20K	-$361.51K	-$4.23M
Net Income	-$20.23K	-$19.20K	-$361.51K	-$4.23M
Diluted EPS	-0.40	-0.01	-0.26	-3.40
Diluted Shares	2.10M	2.10M	2.10M	1.27M

CURX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.43K	$74.37K	$148.89K	$4.97M
Receivables	$3.00K	$0.00	—	—
Inventory	$2.99K	$0.00	—	—
Current Assets	$10.23K	$74.37K	$517.93K	$11.23M
Total Assets	$10.23K	$74.37K	$517.93K	$11.58M
Current Liabilities	$0.00	$14.28K	$14.57K	$137.03K
Total Debt	—	—	$0.00	$346.70K
Total Liabilities	$0.00	$14.28K	$14.57K	$361.04K
Retained Earnings	-$241.75K	-$260.94K	-$622.45K	-$4.85M
Shareholders' Equity	$10.23K	$60.09K	$503.36K	$11.22M
Working Capital	$10.23K	$60.09K	$503.36K	$11.09M

CURX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$3.34K	-$120.00	-$555.58K	-$10.48M
Free Cash Flow	$3.34K	-$120.00	-$555.58K	-$10.48M
Depreciation & Amortisation	$21.16K	$1.81K	$0.00	$79.40K
Financing Cash Flow	-$3.00K	$72.06K	$630.10K	$15.31M
Net Change in Cash	$336.00	$71.94K	$74.53K	$4.82M

CURX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$0.00	$0.00	$677.47K	$2.31M	$2.26M	$2.59M
Selling, General & Admin	$137.45K	$57.66K	$273.85K	$786.34K	$927.20K	$731.84K
Operating Expenses	$137.45K	$57.66K	$951.33K	$3.09M	$3.18M	$3.33M
Operating Income	-$137.45K	-$57.66K	-$951.33K	-$3.09M	-$3.18M	-$3.33M
EBITDA	-$121.59K	-$42.23K	-$934.53K	-$3.04M	-$3.12M	-$3.25M
Pretax Income	-$137.58K	-$60.35K	-$954.06K	-$3.07M	-$3.15M	-$3.29M
Net Income	-$137.58K	-$60.35K	-$954.06K	-$3.07M	-$3.15M	-$3.29M
Diluted EPS	-0.00	-0.04	-0.80	—	-2.20	-2.40
Diluted Shares	27.75M	1.39M	1.28M	—	1.42M	1.42M

CURX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$198.94K	$108.86K	$5.83M	$4.97M	$4.02M	$2.94M
Current Assets	$696.07K	$711.34K	$14.42M	$11.23M	$8.09M	$4.79M
Total Assets	$786.94K	$787.17K	$14.48M	$11.58M	$8.41M	$5.07M
Current Liabilities	$192.60K	$75.93K	$185.96K	$137.03K	$128.73K	$104.31K
Long-Term Debt	$200.00K	$400.00K	—	—	—	—
Total Debt	$291.18K	$476.45K	$61.15K	$346.70K	$311.00K	$276.36K
Total Liabilities	$421.16K	$481.74K	$185.96K	$361.04K	$332.64K	$286.25K
Retained Earnings	-$760.03K	-$820.38K	-$1.77M	-$4.85M	-$8.00M	-$11.29M
Shareholders' Equity	$365.78K	$305.43K	$14.29M	$11.22M	$8.08M	$4.79M
Working Capital	$503.47K	$635.41K	$14.23M	$11.09M	$7.96M	$4.69M
Net Debt	$1.06K	$291.14K	—	—	—	—

CURX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$149.95K	-$290.08K	-$9.19M	-$857.40K	-$954.56K	-$1.08M
Free Cash Flow	-$149.95K	-$290.08K	-$9.19M	-$857.40K	-$954.56K	-$1.08M
Depreciation & Amortisation	$14.63K	$15.03K	$15.44K	$34.29K	$35.04K	$36.64K
Stock-Based Compensation	$0.00	$0.00	—	—	$9.79K	$0.00
Financing Cash Flow	$200.00K	$200.00K	$14.91M	$0.00	$0.00	$0.00
Net Change in Cash	$50.05K	-$90.08K	$5.72M	-$857.40K	-$954.56K	-$1.08M

Market Snapshot

About

Curanex Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. The company's research and development efforts target treatments for various diseases and medical conditions. Curanex Pharmaceuticals pursues both proprietary drug candidates and licensing opportunities to build its product pipeline. The company operates in the competitive pharmaceutical development sector, where successful candidates must navigate lengthy clinical trials and regulatory approval processes.